Glenmark has filed a product for a clinical trial with India’s Drug regulatory body DCGI and became the first company in India to receive approval for conducting Covid-19 patients treatment. The drug Favipiravir has been tested successfully and it will be available in the upcoming weeks.
Many Pharmaceutical companies have launched generic versions of Remdesivir and Favipiravir for Covid-19 treatment, experts said that the results have shown a positive impact on the patients. The pharmaceutical companies have received approval to manufacture and market this drug meanwhile, Glenmark has launched this drug under the brand name FabiFlu, an oral medication.
According to the press release, Glenmark has issued approval on 20 June and the company has developed the ingredients successfully in its own in-house.
FabiFlu is the first approved oral medication for Covid-19 patients, after getting approval from DCGI this antiviral drug will be marketed to different parts of the country. The approval has come at the right time when Covid-19 cases are increasing like never before.
What is Favipiravir’s oral medication?
This antiviral medication was first developed in Japan for treating Influenza, now it is tested on more than 15 clinical trials for Covid-19 till now most of the studies reflect positive results.
This drug is said to control the effects of Covid-19 patients within four days. It has shown more than 80% of clinical improvements in Covid-19 patients with mild to moderate symptoms. This medicine will be administered to patients between 18-75 years of age.
Glenmark Pharma said that Covid-19 patients with co-related conditions such as heart diseases or diabetes can also have this medicine. Fabiflu 200 mg is a prescription based medication, the recommended dose is 200 mg daily twice and it will be followed by 800 mg up to the next 14 days.
Why does Favipiravir work effectively?
This drug has efficacy as it works by preventing the virus from duplicating its genetic material. This drug showed strong inhibitory action against fever and cough. RNA polymerase or RNA dependent on most of the viruses with RNA genome. It proved as effective medication during flu.
As per medical experts, Favipiravir is the game-changer for Covid-19 patients. This medication has to be given in the early days of the treatment and it can be given in the form of a tablet.
Initially, Favipiravir 200 mg will be available at the hospitals and retail stores. The price for 1 strip will cost Rs 3500 as Glenmark said.
The improvement was shown in Covid-19 patients with Favipiravir 200mg tablet
Glenmark said that Favipiravir has shown improvements in the Covid-19 patients with a rapid boost in the recovery. This drug was tested on Indian patients to know the drug’s potency and standard safety care of patients. This study has enrolled more than 100 patients and results are yet to be disclosed.
This drug has shown rapid recovery and relieved the patients from extreme fever and cough.
Presently Glenmark’s priority is to capture the Indian market and later it will export the drug.
Read:- Branded Medication vs Generic Medication vs Branded Generic
I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
ReplyDeleteliver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers.